Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lu-177 PSMA”

101 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 101 results

Early research (Phase 1)Looking for participantsNCT07223034
What this trial is testing

177Lu-PSMA-617 in People With Gliomas

Who this might be right for
GliomaDiffuse Astrocytoma, IDH-Wildtype (Grade 2-4)Glioblastoma, IDH-wildtype+3 more
Memorial Sloan Kettering Cancer Center 20
Testing effectiveness (Phase 2)Looking for participantsNCT06866938
What this trial is testing

Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Hospices Civils de Lyon 58
Testing effectiveness (Phase 2)Study completedNCT04291300
What this trial is testing

Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients

Who this might be right for
Salivary Gland CancerSalivary Duct CarcinomaAdenoid Cystic Carcinoma
Radboud University Medical Center 12
Early research (Phase 1)Study completedNCT06641219
What this trial is testing

Clinical Evaluation of [177Lu]Lu-BQ7876 for Targeting of Prostate-Specific Membrane Antigen

Who this might be right for
Prostate Cancers
Tomsk National Research Medical Center of the Russian Academy of Sciences 7
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05896371
What this trial is testing

Personalized PSMA Radiopharmaceutical Therapy

Who this might be right for
CancerProstate CancerMetastatic Cancer+1 more
CHU de Quebec-Universite Laval 500
Not applicableLooking for participantsNCT07169825
What this trial is testing

Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function

Who this might be right for
Lu-177 PSMA
M.D. Anderson Cancer Center 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07441837
What this trial is testing

Terbium 161 PSMA in Lutetium-177 PSMA Naive Patients

Who this might be right for
Prostate Cancer
Ankara University 60
Testing effectiveness (Phase 2)UnknownNCT04188587
What this trial is testing

177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Nanjing First Hospital, Nanjing Medical University 30
Testing effectiveness (Phase 2)WithdrawnNCT06329830
What this trial is testing

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer

Who this might be right for
Metastatic Prostate CancerCastration-resistant Prostate CancerMetastatic Castration-resistant Prostate Cancer
Baptist Health South Florida
Testing effectiveness (Phase 2)UnknownNCT05150236
What this trial is testing

EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC

Who this might be right for
Prostatic NeoplasmsGenital Neoplasms, MaleUrogenital Neoplasms+4 more
Australian and New Zealand Urogenital and Prostate Cancer Trials Group 93
Testing effectiveness (Phase 2)Looking for participantsNCT06004661
What this trial is testing

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT07047118
What this trial is testing

JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostatic Cancer, Castration-Resistant
Novartis Pharmaceuticals 134
Testing effectiveness (Phase 2)Looking for participantsNCT07226986
What this trial is testing

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Who this might be right for
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals 123
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05570994
What this trial is testing

177Lu-HTK03170 in mCRPC With PSMA Positive Disease

Who this might be right for
Metastatic Castration-resistant Prostate CancerProstate Cancer MetastaticCastrate Resistant Prostate Cancer
British Columbia Cancer Agency 50
Not applicableStudy completedNCT06461689
What this trial is testing

Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Prostate Cancer Metastatic
Central Hospital, Nancy, France 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT05114746
What this trial is testing

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 94
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07310355
What this trial is testing

68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Chengdu StarRay Therapeutics Co., Ltd 49
Testing effectiveness (Phase 2)Active Not RecruitingNCT05547061
What this trial is testing

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy

Who this might be right for
Prostate CancermCRPC
Cellbion Co., Ltd. 91
Not applicableLooking for participantsNCT06850545
What this trial is testing

Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer

Who this might be right for
Metastatic Prostate AdenocarcinomaPSMA PET-Positive Castration-Resistant Prostate Cancer
Kuopio University Hospital 150
Testing effectiveness (Phase 2)Active Not RecruitingNCT06894511
What this trial is testing

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 7
Load More Results